Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Syndrome

NCT03708900 is registered in ClinicalTrials.gov with RECORDATI GROUP as lead sponsor.

NCT NCT03708900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03708900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Syndrome
Lead sponsor
RECORDATI GROUP
Phase
Phase 2
Overall status
Recruiting
Start date
April 28, 2021
Completion date
July 21, 2027
Enrollment
12 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cushing syndrome